Clinical Data TD-0714 is the lead molecule in Theravance's neprilysin inhibitor program for the treatment of cardiovascular and renal disease.  The data released stated "Evidence of biological effect, sustained elevations of cGMP (a well-precedented biomarker of NEP target engagement) over 24 hours in both plasma and urine at all dose levels, low levels of renal elimination, and a favorable safety profile".  The data overall showed safety and tolerability in the patients.